EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular typing of stage IB non-small-cell lung cancer for precision medicine

Xiaoyan Li, Zitong Wan, Miaomiao Wen, Jianfei Zhu, Kaiqi Wei, Xiaohong Ji, Jiao Zhang, Guoyin Li, Jie Lei, Yangbo Feng, Yanlu Xiong, Yinxi Zhou und 1 weitere

Frontiers in Oncology · 13.03.2026 · 16

DOI: 10.3389/fonc.2026.1605054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 13.03.2026. Verfasst von Xiaoyan Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Transfusion, Shanxi Provincial People's Hospital, Taiyuan, China. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal postoperative management of stage IB non-small-cell lung cancer (NSCLC) remains controversial due to significant heterogeneity. This study aimed to establish a molecular classification for stage IB NSCLC to guide precision medicine.

Methods

We performed consensus clustering of transcriptomic profiles from TCGA-NSCLC (training set, n=119) and validated in GSE31210 (n=53). Molecular subtypes were compared with stage IA/II patients for clinical significance. Differentially expressed genes were analyzed using LASSO regression to identify biomarkers. Functional studies were conducted using patient-derived organoids (PDOs), cell lines, and tissue specimens.

Results

Stage IB NSCLC was divided into two subtypes (IB1 and IB2) with significantly different disease-free survival (DFS). IB1 patients showed DFS similar to stage IA, while IB2 patients exhibited DFS comparable to stage II (especially IIB). Carboxypeptidase D (CPD) was identified as a key biomarker capable of distinguishing high- and low-risk patients (AUC=0.874 in validation). CPD was overexpressed in tumor tissues and promoted proliferation and migration in PDOs and cell lines.

Conclusion

This molecular classification effectively stratifies stage IB NSCLC into low-risk (IB1, observation suitable) and high-risk (IB2, adjuvant therapy warranted) subgroups. CPD serves as a promising biomarker for clinical risk stratification.

Schlagwörter

Stichwörter der Autor:innen

carboxypeptidase Dmolecular typingnon-small-cell lung cancerprognosisstage IB

Autor:innen und Institutionen

  • Department of Blood Transfusion, Shanxi Provincial People's Hospital, Taiyuan, China.
  • Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
  • Department of Thoracic Surgery, Shaanxi Provincial People's Hospital, Xi'an, China.
  • College of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, China.
  • Academy of Medical Science, Zhengzhou University, Zhengzhou, China.
  • Innovation Center for Advanced Medicine, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.

Zitieren

APA

Li, X., Wan, Z., Wen, M., Zhu, J., Wei, K., Ji, X., Zhang, J., Li, G., Lei, J., Feng, Y., Xiong, Y., Zhou, Y., & Xin, S. (2026). Molecular typing of stage IB non-small-cell lung cancer for precision medicine. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1605054

Vancouver

Li X, Wan Z, Wen M, Zhu J, Wei K, Ji X, et al. Molecular typing of stage IB non-small-cell lung cancer for precision medicine. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1605054

BibTeX
@article{Li2026,
  author = {Li, Xiaoyan and Wan, Zitong and Wen, Miaomiao and Zhu, Jianfei and Wei, Kaiqi and Ji, Xiaohong and Zhang, Jiao and Li, Guoyin and Lei, Jie and Feng, Yangbo and Xiong, Yanlu and Zhou, Yinxi and Xin, Shaowei},
  title = {Molecular typing of stage IB non-small-cell lung cancer for precision medicine},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1605054}
}
Kostenlos starten →